December 2016
-
The Medicon Valley Inhalation Consortium (MVIC) has announced that Ola Nerbrink has succeeded Orest Lastow as CEO. Nerbrink was previously MVIC’s VP of Business Development. Lastow, who founded MVIC in 2012, left the position in… Read more . . .
-
Molins Technologies has announced the addition of the disk format µ-check to their µ-check line of check weighers. The standard µ-check can weigh individual DPI blisters alone or in blister strips. The new µ-check machine… Read more . . .
-
Sandoz has announced that the Mexican health authority, COFEPRIS, has approved the company’s marketing application for the Airflusal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and for COPD. Three dosage levels were approved: 50-100… Read more . . .
-
GlaxoSmithKline has announced that it has received FDA approval for its fluticasone furoate DPI, to be marketed as Arnuity Ellipta, for the maintenance treatment of asthma. The approval is for 100mcg and 200mcg doses and… Read more . . .
-
The FDA has accepted Boehringer Ingelheim’s New Drug Application for its tiotropium/olodaterol Respimat soft mist inhaler for the treatment of COPD, the company has announced. BI’s Striverdi Respimat olodaterol SMI was approved by the FDA… Read more . . .
-
The United States Pharmacopeial Convention (USP) has announced three recipients of its 2014–2015 Global Fellowship Awards. One of the recipients of the $30,000 fellowship, Ahmed Shalash of Alexandria University in Alexandria, Egypt, is researching carriers… Read more . . .
-
In addition to its 20% acetylcysteine solution products, Fresenius Kabi is now offering 4 ml, 10 ml, and 30 ml vials of acetylcysteine 10% for oral use or inhalation in the US. Acetylcysteine is a… Read more . . .
-
The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 10-3 to approve Boehringer Ingelheim’s Spiriva Respimat tiotropium soft mist inhaler for the treatment of COPD. BI’s first NDA submission for tiotropium Respimat took place in… Read more . . .
-
Skyepharma says that it will begin developing a COPD therapy based on Pulmagen’s ICS “re-sensitization” technology (SKP-2075) by the end of 2014 after acquiring the IP and global rights to the Theocort platform from Pulmagen.… Read more . . .
-
CDMO Formex, LLC has announced that former Azo Pharma VP of Formulation Development John McCarty has joined the company as Scientific Advisor. McCarty will also serve as a member of the company’s Science Advisory Board.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland